Drug Use Investigation For HIV Infection Patients Of Mycobutin (Regulatory Post Marketing Commitment Plan)

Trial Profile

Drug Use Investigation For HIV Infection Patients Of Mycobutin (Regulatory Post Marketing Commitment Plan)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Rifabutin (Primary)
  • Indications Mycobacterial infections; Mycobacterium avium complex infections; Tuberculosis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Aug 2017 Planned End Date changed from 1 May 2018 to 17 Jul 2018.
    • 16 Aug 2017 Planned primary completion date changed from 1 May 2018 to 17 Jul 2018.
    • 05 Jan 2016 Planned End Date changed from 1 Apr 2018 to 1 May 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top